Navigation Links
Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
Date:3/12/2008

VIENNA, Austria, March 12 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it will open a research facility in Cambridge, UK in addition to its headquarters in Vienna, Austria. The facility will be located at the Babraham Research Campus, home to a number of biotech companies and close to the Medical Research Council's Laboratory of Molecular Biology (LMB), the major center for antibody engineering in Europe.

The research site will start operations on April 15, 2008. The group located in Cambridge will mainly be responsible for lead generation based on the company's Modular Antibody Technology as well as, in the future, for research related to the conduct of collaborative studies between f-star and its pharma and biotech partners.

f-star's Cambridge site will start with a small group of highly experienced researchers in the field. The research group will be headed by Lutz Riechmann, a senior researcher with over 20 years of experience in antibody research in Sir Gregory Winter's group at the LMB.

"We are excited to open up a lab at the epicenter of Europe's antibody research and development community and to utilize the large pool of talent and experience concentrated in the Cambridge area," says Gottfried Himmler, CEO.

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAb2) can be created.

f-star was founded by a team of experienced antibody engineering and biotech executives in 2006. Seed-financed by Austrian government agencies and Atlas Venture, the company recently closed a Series A financing round with Aescap Venture, Atlas Venture and Novo A/S and has raised EUR 13.0m in total so far. In its advisory board, the company is supported by pioneers in the field of monoclonal antibodies. f-star has 18 employees at its headquarters in Vienna, Austria and recently opened a second research site in Cambridge, UK.
For more information, visit http://www.f-star.com

Company contact:

Dr. Eugen Stermetz

CFO

f-star Biotechnologische Forschungs- und Entwicklungs-GmbH

+43-72055-4215

Gastgebgasse 5-13

A-1230 Vienna, Austria

office@f-star.com

Media contact:

Frank Butschbacher

Investor Relations & Communications

+43-650-78 44 940

office@butschbacher.net

http://www.butschbacher.net


'/>"/>
SOURCE f-star
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
2. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
3. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
4. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
5. Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer
6. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
7. Abbott Scientists Create One Molecule With Two Antibody Functions
8. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
9. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
10. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):